- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07852728
HBOT Effects on First Responders' Cognition and Well-Being
Changes in Cognitive Functioning, Psychological Well-Being, and Quality of Life Following Hyperbaric Oxygen Therapy in First Responders
The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are:
- Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions?
- Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment?
Approximately 54 participants will:
- Complete medical and behavioral health screening.
- Complete cognitive tests and questionnaires before and after treatment.
- Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions.
All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This prospective, single-arm study will examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in approximately 54 current or former first responders with a history of traumatic brain injury (TBI). Secondary outcomes include symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety, as well as quality of life.
After providing informed consent, participants will undergo medical and behavioral health screening to determine eligibility for HBOT. Eligible participants will complete baseline cognitive testing and questionnaires measuring post-concussive symptoms, psychological symptoms, and quality of life. These assessments will be repeated after treatment.
Participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen separated by a 5-minute air break. Sessions will take place twice daily, Monday through Friday, with at least four hours between sessions. A physician will prescribe and oversee treatment, and trained hyperbaric personnel will operate the chamber and monitor participants.
Changes between baseline and post-treatment assessments will be analyzed within participants. The study will also explore whether demographic or clinical characteristics are associated with the magnitude of change. All participants will receive HBOT; there is no randomized or untreated comparison group. As a result, the study can describe changes observed following treatment but cannot establish that HBOT caused those changes.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Troy Nickel, Ph.D.
- Número de teléfono: 208-813-9541
- Correo electrónico: tnickel@shwidaho.org
Ubicaciones de estudio
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83716
- Reclutamiento
- Summit Hyperbarics and Wellness
-
Contacto:
- Troy Nickel, Ph.D.
- Número de teléfono: 208-813-9541
- Correo electrónico: tnickel@shwidaho.org
-
Investigador principal:
- Steve Wyman, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria
- Adults aged 18 to 75 years.
- Current or former first responder.
- Clinically diagnosed with a traumatic brain injury (TBI) and current or persistent post-concussive syndrome, as determined by a qualified health care professional.
- Participants with comorbid PTSD, depression, or anxiety may be enrolled if all other eligibility criteria are met; these symptoms will be assessed as secondary/exploratory outcomes.
- Ability to provide informed consent, including the ability to read, understand, and voluntarily sign the informed consent document.
- Completion of baseline cognitive and psychological assessment measures as part of study enrollment procedures.
- Presence of clinically significant symptoms resulting in functional impairment in occupational, social, or other key areas of functioning, as determined by clinical evaluation.
- Sexually active female participants of childbearing potential and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of contraception for the duration of the study and for 30 days following the final HBOT session.
- Stable regimen of psychoactive medications (if applicable), including antidepressants, anxiolytics, antipsychotics, stimulants, and mood stabilizers, for a clinically appropriate stabilization period prior to enrollment, as determined by the study physician.
Exclusion criteria
- Untreated pneumothorax
- History of spontaneous pneumothorax
- Severe sinus infection
- Upper respiratory infection
- Asymptomatic pulmonary lesions on chest x-ray
- Uncontrollable high fever (greater than 39C)
- History of chest or ear surgery
- Congenital spherocytosis
- Any anemia or blood disorder
- Any convulsive disorder
- History of optic neuritis or sudden blindness
- Middle ear infection
- Diabetes mellitus (insulin therapy)
- The participant is pregnant or lactating
- Nicotine use/substance use/addiction
- Acute Hypoglycemia
- Diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Emphysema
- Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds.
- Active malignancy
- Current manic, delusional, or psychotic episodes
- Serious/current suicidal ideations
- Severe or unstable physical disorders or major cognitive deficits
- Inability to attend scheduled clinic visits or comply with study protocols.
- Treated with HBOT for any reason prior to study enrollment.
- Non-English speakers
- History of retinal repair, including laser photocoagulation or retinal detachment surgery.
- History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement.
- Age greater than 75 years.
- Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapuetic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Hyperbaric Oxygen Therapy
Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment. |
Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in NeuroTrax Global Cognitive Score
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in Global Cognitive Score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in post-concussive symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in PTSD Checklist for DSM-5 (PCL-5) score
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in PTSD symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) score
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in depression symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) score
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in anxiety symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) domain scores
Periodo de tiempo: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in quality-of-life scores from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Steve Wyman, MD, Summit Hyperbarics and Wellness
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos relacionados con el trauma y el estrés
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Heridas y Lesiones
- Síntomas de comportamiento
- Trauma craneoencefálico
- Trauma, Sistema Nervioso
- Traumatismos craneales, Cerrado
- Heridas No Penetrantes
- Lesiones Cerebrales
- Trastornos de Estrés, Traumáticos
- Contusión cerebral
- Comportamiento
- Lesiones Cerebrales Traumáticas
- Desórdenes de ansiedad
- Depresión
- Síndrome posterior a la conmoción cerebral
- Trastornos de estrés postraumático
- Trastornos de combate
- Terapéutica
- Terapia respiratoria
- Terapia con inhalación de oxígeno
- Oxigenación hiperbárica
Otros números de identificación del estudio
- HBOT-FR-2026-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
There is no current plan to share IPD outside the study team. Given the relatively small sample of first responders and the sensitive clinical and occupational information collected, sharing participant-level data could increase the risk of re-identification. Study findings will be reported in aggregate.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .